Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03732287 · ClinicalTrials.gov registry record · Phase 1
Cooling Anesthesia for Intravitreal Injection
A Phase 1 study of Diabetic Macular Edema and Macular Degeneration, sponsored by Recens Medical.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT03732287 is a Phase 1 study of Diabetic Macular Edema and Macular Degeneration that has completed, run by Recens Medical. The registered enrollment target is 40 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03732287, a Phase 1 study of Diabetic Macular Edema and Macular Degeneration, has completed, sponsored by Recens Medical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this clinical study is to evaluate the safety and efficacy of cooling anesthesia application to the eye as anesthesia for intravitreal injection using a novel cooling anesthesia device and determine the effects of temperature and duration of application on subjective pain after intravitreal injection.
Conditions Studied
Interventions
- DEVICE Cooling Anesthesia
Study Locations (2)
Nevada
- Sierra Eye Associates - Reno
Texas
- Retina Consultants of Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-11-30 |
| Est. Completion | 2019-04-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03732287
The ClinicalTrials.gov registry entry for NCT03732287 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The listed sponsor is Recens Medical, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which Cooling Anesthesia is the first listed.
NCT03732287 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Nevada, Texas.
Frequently Asked Questions
What is clinical trial NCT03732287 about?
NCT03732287 is a clinical study titled "Cooling Anesthesia for Intravitreal Injection". The purpose of this clinical study is to evaluate the safety and efficacy of cooling anesthesia application to the eye as anesthesia for intravitreal injection using a novel cooling anesthesia device and determine the effects of temperature and duration of application on subjective pain after intrav...
What is the current status of trial NCT03732287?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2018-11-30. Estimated completion is 2019-04-26.
What conditions does trial NCT03732287 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Macular Degeneration, Anesthesia, Local, Intravitreal Injection.
What interventions are being tested in trial NCT03732287?
The interventions under investigation include: Cooling Anesthesia (DEVICE).
Who is sponsoring clinical trial NCT03732287?
This trial is sponsored by Recens Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03732287 being conducted?
This trial has 2 study locations across Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.